[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholesterol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholesterol":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,76,121,145,161,193,220,255,282],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100456084","health-related-benefits-of-introducing-table-olives-into-the-diet-of-young-adults-olives-for-health-100456084",false,"NCT05218980","Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health","Inclusion Criteria:\n\n* Yale College Freshman, Sophomore, or Junior\n* Ability and desire to sign informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, age 18 on the day of consent\n* Ability and desire to consume 6 olives daily\n\nExclusion Criteria:\n\n* Yale College Senior\n* Unable to provide informed consent form\n* Self-reported pregnancy\n* Unwillingness to comply with all study procedures and\u002For be available for the duration of the study\n* Inability and desire to consistently consume 6 olives per day\n* Inability to consume fruit with pits\n* Current and consistent use of \\> 6 olives per day\n* Current and consistent use of ≥ 1 tablespoon of extra virgin olive oil (EVOO) per day\n* Known allergic reactions to olives and\u002For their derivatives\n* Known reactions to blood draw",true,"ALL","18 Years","23 Years",{"count":20,"type":21},226,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to assess whether introducing table olives into the diet results in health-related benefits for young adults. Several studies have shown that addition of olives as part of somebody's diet has a positive impact on cardiovascular, metabolic, and inflammatory factors. However, there have not been many studies among young, healthy adults. This study will compare levels of specific biomarkers, collected through blood draw, at the beginning of the study and after 5 weeks, to evaluate the effects of investigational daily olive consumption.",[27,28,29,30],"Healthy Diet","Cholesterol","Healthy Lifestyle","Healthy Nutrition",[32],"olives","NOT_YET_RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-13","ACTUAL",{"date":39,"type":21},"2027-01",{"date":41,"type":21},"2027-06",{"name":43,"class":44},"Yale University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100634461","evaluation-of-a-novel-indoor-air-pollution-intervention-among-older-adults-100634461","NCT07539987","Evaluation of a Novel Indoor Air Pollution Intervention Among Older Adults","Inclusion Criteria:\n\n* 55-79 years of age one primary residence (5+ days per week)\n* have an electronic device, email address, and reliable internet at home for survey submission\n\nExclusion Criteria:\n\n* current smoking of any kind or living in a household with someone who currently smokes\n* current use of a portable air cleaner unit at home\n* plans to move in the next year\n* previous physician-diagnosed cardiovascular disease (coronary heart disease \\[myocardial infarction\\], stroke, or heart failure)","55 Years","79 Years",{"count":55,"type":21},154,[24],"Particulate matter air pollution is the leading environmental risk factor of cardiovascular disease and is increasing in the Western United States due to more frequent and severe wildfires. Older adults are particularly susceptible to both air pollution exposures and the development of cardiovascular disease, and the older adult population in the United States is rapidly growing. Given the converging threats of worsening air quality and an aging population, this clinical trial will evaluate a novel, multifaceted indoor air quality intervention to improve cardiovascular health outcomes among older adults in the wildfire-impacted state of Montana.",[59,60,61,28,62,63,64,65,66],"Cardiovascular Diseases","Blood Pressure","Glycated Hemoglobin (HbA1c)","Cholesterol, HDL","Cholesterol, LDL","Indoor Air Quality","Particulate Matter","Health Behavior","2026-04-13",{"date":69,"type":37},"2026-04-20",{"date":71,"type":21},"2026-08",{"date":73,"type":21},"2030-07",{"name":75,"class":44},"University of Montana",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":101,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100620350","enhancing-mental-and-physical-health-of-women-veterans-30-100620350","NCT07356479","Enhancing Mental and Physical Health of Women Veterans 3.0","Enhancing Mental and Physical Health of Women Through Engagement and Retention (EMPOWER) 3.0 (QUE 25-015)","EMPOWER","Inclusion Criteria:\n\n* This study is recruiting VA sites - not individual patients.\n* Prior to randomization, the study team will work with sites to ensure they have met the preconditions necessary to enroll in the study, which includes VISN, regional and\u002For facility level leadership support for participation.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":85,"type":21},18,[24],"Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.",[59,89,90,91,28,92,93,94,95,96,97,98,99,100],"Overweight","Obesity","Hypertension","Diabetes Mellitus","Prediabetic State","Menopause","Cognitive Behavioral Therapy","Primary Health Care","Stress Disorders, Post-Traumatic","Prevention","Implementation Science","Quality Improvement",[102,89,90,91,28,92,93,94,95,96,97,98,103,100,104,105,106,107,108,109,110,66],"Cardiovascular diseases","Implementation science","Women","Veterans","Patient Participation","Patient Satisfaction","Patient Preference","Physicians, Primary Care","Physicians, Women","2026-01-12",{"date":113,"type":37},"2026-01-21",{"date":115,"type":21},"2026-10-01",{"date":117,"type":21},"2031-09-30",{"name":119,"class":120},"VA Office of Research and Development","FED",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100404420","early-phase-1-positron-emission-tomography-pet-imaging-of-cholesterol-trafficking-clinical-evaluation-of-18ffnp-59-in-normal-human-subjects-groups-2-3--4-100404420","NCT04546126","Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)","Inclusion Criteria (Groups 2 \\& 3):\n\n* Participants without any known adrenal pathology as normal controls for undergoing endocrine manipulation\n\nExclusion Criteria (Groups 2 \\& 3):\n\n* Pregnancy\n* Unable to do imaging\n* Body weight greater than 400 lbs (181 Kg)\n* Prisoners are not eligible\n* Subjects unable to provide own consent are not eligible\n* Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)\u002F Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues.\n* Known adrenal pathology\n\nInclusion Criteria (Group 4):\n\n* Abnormal adrenal cortical hormone secretion\n\nExclusion Criteria (Group 4):\n\n* Pregnant",{"count":128,"type":21},24,[130],"EARLY_PHASE1","This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\\[18F\\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.",[133,91,28],"Radiotracer","RECRUITING","2025-11-27",{"date":137,"type":37},"2025-12-05",{"date":139,"type":37},"2021-11-01",{"date":141,"type":21},"2026-12",{"name":143,"class":44},"Benjamin Viglianti",2,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":160,"locationsCount":45},"100403376","early-phase-1-positron-emission-tomography-pet-imaging-of-cholesterol-trafficking-clinical-evaluation-of-18ffnp-59-in-normal-human-subjects-group-1-100403376","NCT04532489","Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)","Inclusion Criteria:\n\n* Participants without any known adrenal pathology as normal controls for radiation dosimetry purposes\n\nExclusion Criteria:\n\n* Pregnancy\n* Unable to do imaging\n* Body weight greater than 400 lbs (181 Kg)\n* Prisoners are not eligible\n* Subjects unable to provide own consent are not eligible\n* Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)\u002F Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues.\n* Known adrenal pathology",{"count":152,"type":21},6,[130],"This exploratory, first-in-man, phase 0 study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\\[18F\\]FNP-59) to image the adrenal gland in healthy normal subjects. The researchers believe that \\[18F\\]FNP-59 would greatly improve the imaging characteristics, by providing a PET imaging cholesterol analogue with significantly improved radiation dosimetry.",[133,91,28],{"date":137,"type":37},{"date":158,"type":37},"2021-01-18",{"date":141,"type":21},{"name":143,"class":44},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":45},"100586740","the-effect-of-a-digital-heart-health-app-and-lifestyle-intervention-for-heart-disease-in-primary-care-100586740","NCT06919302","The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.","An Innovative Technology-based Approach to Translating Clinical Practice Guidelines of Nutrition Therapy in Primary Care: The Coronary Heart Effectiveness Assessment of the Portfolio Diet in Primary Care (CHEAP) Trial","CHEAP","Inclusion Criteria:\n\n* Be taking statin medication with or without other antihyperlipidemic therapy (stable dose for at least 3-months).\n* Fall under either of the 2 categories:\n\n  1\\) Secondary prevention participants: males and females ≥45 years of age with established atherosclerotic cardiovascular disease (ASCVD) defined as at least one of the following: i. Prior myocardial infarction (MI); ii. Acute coronary syndrome (ACS); iii. Stroke\u002FTIA; iv. Coronary revascularization; v. Documented carotid disease (endarterectomy, carotid stenosis ≥50%); vi. Stable angina; vii. Coronary artery disease (CAD) by angiography; viii. Peripheral artery disease (PAD); ix. Abdominal aortic aneurysm (AAA)\n\n  2\\) High-risk primary prevention participants: males and females ≥50 years of age plus type 2 diabetes requiring treatment with medication and at least one additional risk factor: i. Males ≥55 years of age and females ≥65 years of age; ii. Cigarette smoker or stopped smoking within 3 months before Visit 1; iii. Hypertension and on antihypertensive medication for at least 6-months; iv. Chronic kidney disease (CKD); v. Retinopathy, defined as any of the following: non-proliferative retinopathy, pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or a history of photocoagulation\n* Be on a stable dose for at least 3-months of all antihyperlipidemic, antihyperglycemic, antihypertensive, and antiobesity therapies.\n* Have a family physician in Ontario and a valid Ontario Health Card.\n* Have regular access to an online portal\n* Be proficient in English.\n\nExclusion Criteria:\n\n* Major disease expected to result in death within 2 years (except cardiovascular disease)\n* Active sever liver disease\n* Malabsorption disorders\n* Drug or alcohol abuse disorders (within past 6 months)\n* Intolerance or allergies to soy protein and tree nuts, peanuts, or seeds\n* Planned coronary intervention or any major surgical procedure\n* Participation in another clinical trial (within past 3 months)\n* End stage renal disease (requirement for peritoneal dialysis or hemodialysis for renal insufficiency or eGFR \\\u003C30 mL\u002Fmin)\n* Any condition or therapy which might pose a risk to the patient or make participation in the study not be in the best interest of the patient as assessed by the investigator\n* Documented severe (New York Heart Association \\[NYHA\\] class IV) heart failure\n* Mental\u002Fpsychological impairment expected to affect adherence to the study protocol\n* Known AIDS (HIV-positive patients without AIDS are allowed)\n* Women planning on becoming pregnant within the first year of the intervention\n* Unable to provide informed consent: Appear unable to comprehend the study protocol during the interview process or to understand and communicate in English sufficiently for informed consent.","45 Years",{"count":171,"type":21},1100,[24],"Despite the availability of medications, many people around the world continue to live with long-term health problems like heart disease, stroke and diabetes. In Canada, heart disease is a leading cause of death. Managing these health issues can be done by changing diet and lifestyle. Specific ways of eating have been proven to improve risk for heart disease and stroke. However, because doctors often have limited time, nutrition education, and lack of tools for counseling patients on nutrition, they can often only provide minimal support to help patients make necessary lifestyle changes. Digital tools and mobile applications offer an opportunity to involve doctors and patients in delivering nutrition interventions. This approach has the potential to save time, provide education, and reduce healthcare costs. This study is being done to understand the effect of a digital heart health program added to standard of care, compared with standard of care alone on heart health. All eligible participants in this study will be randomized (determined by chance) to one of two possible interventions: 1) a digital heart health program + standard of care; 2) standard of care. Standard is care is defined as the best practice based on guidelines for the treatment of a condition. All participants will be followed for seven years and will be asked to complete online questionnaires and complete blood work at their nearest LifeLabs clinic, as well as wear a continuous glucose monitor and wrist actigraph (at 3 time points in the first year). In addition, participants randomized to the digital heart health program + standard of care will be expected to use the heart health app and join 16 online synchronous sessions over the first year.\n\nAfter seven years, the intervention phase of the study will end and the study will become a cohort study. All participants at the 7-year time point will be invited to use the heart health app. As part of the cohort study, participants will be asked to continue completing the same questionnaires online and completing bloodwork at their nearest LifeLabs every four years for the duration of their participation in the cohort study.\n\nThe main questions this study aims to answer are:\n\n1. Will a digital heart health program added to standard of care result in a clinically meaningful reduction in blood cholesterol and other risk factors after 1-year compared to standard of care alone?\n2. Will a digital heart health program added to standard of care result in a reduction in major cardiovascular events after 7-years compared to standard of care alone?\n3. Are the observed effects sustained beyond the 7-years of the intervention?\n\nWe hypothesize that the digital heart health program added to standard of care will result in a clinically meaningful reduction in blood cholesterol and other risk factors for heart disease after 1-year and reduce major cardiovascular events after 7-years compared to standard of care alone.",[59,175,176,28,177],"Cardiovascular Risk Factors","Dyslipidemia","Major Cardiovascular Event",[179,180,181,182,183],"randomized controlled trial","digital heart health program","heart health app","web-based app","large-scale study","2025-11-20",{"date":186,"type":37},"2025-11-26",{"date":188,"type":37},"2025-08-15",{"date":190,"type":21},"2035-06-01",{"name":192,"class":44},"University of Toronto",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100612380","identification-of-asymptomatic-patients-at-very-high-cardiovascular-risk-contribution-of-a-strategy-based-on-carotid-and-coronary-explorations-compared-to-simple-risk-calculation-using-the-european-score-2-algorithm-idea-cvr-100612380","NCT07252830","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm. (IDEA-CVR)","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm.","IDEA-CVR","Inclusion Criteria:\n\n* Age \\> 40 years and \\\u003C 80 years referred to general cardiology consultation\n* LDL-C level \\> 1.6 g\u002FL, or LDL-C level \\> 1.3 g\u002FL with at least one associated major cardiovascular (CV) risk factor (RCF) (smoking, hypertension, diabetes).\n* Coronary artery reserve assessment and EDTSA performed in a day hospital\n\nExclusion Criteria:\n\n* Known or suspected carotid atherosclerotic disease\n* Significant ischemic heart disease known or suspected at the time of the initial consultation\n* Protected adult patient (patient under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision)\n* Opposition expressed by the patient to the use of their health data.\n* Patient may have limited understanding of the information sheet","40 Years","80 Years",{"count":204,"type":21},1000,"OBSERVATIONAL","To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months\u002Fyears preceding the acute event.\n\nAccording to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the \"very high CV risk\" category, with an LDL-cholesterol target of \\\u003C0.55 g\u002FL. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.\n\nIn current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European \"SCORE 2\" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.\n\nThe main objective of this study is to describe patients reclassified as \"very high CV risk\" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.",[208,209,28,210],"Myocardial Infarction","Atheroma","Cardiovascular (CV) Risk","2025-11-19",{"date":213,"type":37},"2025-11-28",{"date":215,"type":37},"2021-09-12",{"date":217,"type":21},"2026-01-20",{"name":219,"class":44},"Elsan",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":205,"phases":4,"briefSummary":231,"conditions":232,"keywords":241,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":45},"100571925","interprofessional-pharmacogenomics-ipgx-registry-and-repository-100571925","NCT06726590","Interprofessional Pharmacogenomics (IPGx) Registry and Repository","The Texas Interprofessional Pharmacogenomics Registry and Repository","IPGx Registry","Inclusion Criteria:\n\n* The study will invite patients who are eligible for PGX workup\u002FPGX care to participate, provided they meet the following criteria: Use of five or more medications, including over the counter drugs, supplements, natural products, cannabis products, or other recreational drugs, or\n* Individuals taking blood pressure or depression medications, even if less than five medications.\n* Ability to understand and give consent.\n* Able to consent to donate blood and\u002For urine samples and buccal swabs.\n* Able to answer detailed questionnaires, including quarterly questionnaires about ADRs, cognitive testing such as serial mini-mental status exams, and or quality of life questions.\n* Able to understand that their health record and changes in health status will be followed for a five-year period and shared in deidentified form with the research community.\n* All genders.\n* Any age over 18 years.\n\nExclusion Criteria:\n\n* Individuals admitted to hospice.\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record as this indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning.,\n* Individuals who are unable or unwilling to provide consent.\n* Unable to verbally communicate and comprehend English language",{"count":229,"type":21},3000,"6 Months","This program collects genetic and health information to help doctors choose the right medications for patients.",[233,28,234,235,236,237,238,239,240],"Diabetes","Cancer","Blood Pressure Disorders","Heart Disease","Respiratory Ilness","COPD","Adverse Drug Reaction (ADR)","Poly Pharmacy",[242,243,244,245],"REGISTRY","REPOSITORY","POLYPHARMACY","ADVERSE DRUG REACTION","2025-09-05",{"date":248,"type":37},"2025-09-12",{"date":250,"type":21},"2025-11",{"date":252,"type":21},"2029-11",{"name":254,"class":44},"Texas A&M University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":15,"sex":16,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":280,"locationsCount":45},"100600728","whey-protein-comparisons-for-blood-lipid-effects-100600728","NCT07101263","Whey Protein Comparisons for Blood Lipid Effects","Hydrolyzed Whey for Blood Lipid Control","Inclusion Criteria:\n\n* Cholesterol reading of 190 to 225 mg\u002FdL\n* Age 21-59 years old\n\nExclusion Criteria:\n\n* Uncontrolled diabetes\n* Hypothyroidism or other hormonal problems that have not stabilized\n* Any liver diseases being actively treated\n* Cancer\n* Renal dialysis use\n* Rheumatoid arthritis and related issues like lupus\n* Inflammatory bowel disease\n* Smoking\n* Following a very restrictive diet\n* Low blood pressure\n* Statin drug use\n* Having more than 5 alcoholic drinks per week\n* Extreme obesity (BMI over 37)\n* Pregnancy or lactation\n* Allergies to milk protein\n* History of discomfort after consuming whey protein","21 Years","59 Years",{"count":265,"type":21},72,[24],"The goal of this clinical trial is to learn if hydrolyzed whey protein can help serum cholesterol stay in normal range in adults. As a side inquiry, a few blood measures will be taken that are relevant to low level inflammation. The main questions the study aims to answer are:\n\n* Will hydrolyzed whey lower serum cholesterol readings in adults with starting values in the upper end of normal to the lower end of elevated?\n* Will the hydrolyzed whey affect a general measure of inflammation and two measures of indirect relevance to inflammation?\n\nResearchers will compare hydrolyzed whey to a conventional whey (a control protein not expected to affect serum cholesterol readings) to see if the hydrolyzed whey lowers serum cholesterol.\n\nParticipants will:\n\n* Drink one protein beverage every day for 6 weeks;\n* Go to a LabCorp facility for a blood draw before and after the 6 weeks.",[28],[28,270,271,272,273],"Whey","inflammation","Moderately elevated cholesterol","High end normal cholesterol","2025-08-05",{"date":276,"type":37},"2025-08-08",{"date":274,"type":37},{"date":279,"type":21},"2026-01-15",{"name":281,"class":44},"Medinutra LLC",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":15,"sex":16,"minAge":262,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":45},"100567713","phase-1-natural-heart-health-supplement-trial-100567713","NCT06671769","Natural Heart Health Supplement Trial","Exclusion Criteria:\n\n* Individuals with known soy allergies\n* Individuals with liver disease\n* Pregnant or breastfeeding individuals",{"count":289,"type":21},60,[291],"PHASE1","We are running a 3-month trial of an experimental natural heart health supplement. Participants will take a daily dose of an experimental natural heart health supplement in powdered format, chocolate flavor. The trial will assess changes in heart biomarkers such as Total Cholesterol, HDL-C, LDL-C, Triglycerides, and High-Sensitivity C-reactive protein (hs-CRP).",[28,294],"Cholesterol (total and HDL)",[296],"heart health","2024-11-01",{"date":299,"type":37},"2024-11-04",{"date":301,"type":21},"2025-01-15",{"date":303,"type":21},"2025-05-01",{"name":305,"class":306},"Efforia, Inc","INDUSTRY"]